Skip to content
DataLookout
Menu

NCT04922736

Patient Reported Outcomes With UVA-1 Therapy for Treatment of Sclerosing Skin Diseases

StatusActive, Not Recruiting
PhaseNot applicable
Primary completion (estimated)

At risk: Primary completion moved at least 11 months later.

Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 10 versions: 8 with changes below, 2 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Notable Primary and study completion pushed from Jun 2026 to Jun 2027 Show 5 more changesShow less
    • Eligibility criteria expanded, about 10 words
    • Trial arms changed: 0 → 1
    • Secondary endpoints: details revised at 5 of 5 entries
    • Study description expanded, about 9 words
    • Publications: details revised at 12 of 13 entries
  2. Minor Trial status: Enrolling by Invitation to Active, Not Recruiting
    • Primary and study completion dates: Dec 2025 to Jun 2026
    v8
  3. Notable Primary and study completion dates: Dec 2024 to Dec 2025v7
  4. Minor Primary and study completion dates pushed to Dec 2024v6
  5. Notable Primary completion date: Jun 2023 to Jun 2024
    • Study completion date: Sep 2023 to Sep 2024
    v4
Show 2 earlier versionsHide 2 earlier versions
  1. Notable Trial status: Not Yet Recruiting to Enrolling by Invitation
    • Study sites: 0 to 1
    • Start date changed from estimate of Jun 2021 to Jun 7, 2021
    v3
  2. Minor Study description shortened, about 17 wordsv2
  1. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Evaluate change in the Health Assessment Questionnaire Disability Index (HAQ-DI) after 30 sessions of UVA-1 therapy in treating systemic Scleroderma, morphea, and sclerodermatous graft vs. host disease.
Timeframe: 100 days

Secondary (5)

Assess changes in the Hand Mobility in Scleroderma (HAMIS) score in patients with hand involvement after 30 sessions of UVA-1 therapy.
Assess changes in the Localized Scleroderma Assessment Tool (LoSCAT) score in morphea patients after 30 sessions of UVA-1 therapy.
Assess changes in the Modified Rodnan Skin Score (mRSS) in systemic scleroderma patients after 30 sessions of UVA-1 therapy.
Assess changes in the National Institutes of Health (NIH) Likert scale score in GVHD patients after 30 sessions of UVA-1 therapy.
Assess changes in durometer scores in all patients after 30 sessions of UVA-1 therapy.

Arms and interventions

All Study ParticipantsExperimental

All enrolled participants will receive UVA-1 phototherapy using a UVA-1 light box two to three times per week for a total of 30 treatment sessions over a 100-day period. The initial UVA-1 dose and subsequent dose increases will be determined according to usual clinical practice and the participant's type of sclerotic disease. Treatment will be held for active redness, burning, pain, or blistering at the treatment site. If symptoms have resolved by the next scheduled treatment, the UVA-1 energy will be reduced by 10 J from the previously delivered dose. Dose escalation may resume after three well-tolerated treatments.

Devices: UVA-1 Phototherapy

Sites

1 site in 1 country

  • University of Utah DermatologyMurray, Utah, United States